Integrating New Therapies Into the Management of Relapsed/Refractory Myeloma: Experts Address FAQs

In this episode, Paul G. Richardson, MD; Nina Shah, MD; and Peter M. Voorhees, MD, answer questions from a live webinar providing their thoughts on how to select the optimal therapy for patients with relapse/refractory multiple myeloma. Topics include:

• Treatment after first relapsed
• Optimal use of CAR T-cell therapy
• When to use selinexor and belantamab mafodotin
• COVID-19 vaccinations for patients with myeloma

Presenters:

Paul G. Richardson, MD
R. J. Corman Professor of Medicine
Harvard Medical School
Clinical Program Leader
Director of Clinical Research
Jerome Lipper Multiple Myeloma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Nina Shah, MD
Professor of Clinical Medicine
Division of Hematology-Oncology
Department of Medicine
University of California San Francisco
San Francisco, California

Peter M. Voorhees, MD
Director, Medical Operations and Outreach Services
Department of Hematology/Oncology
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb, GlaxoSmithKline, Karyopharm, Oncopeptides, and Sanofi Genzyme.

Link to full program:
https://bit.ly/2UIhXcL

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.